Holen Sie sich die Stockscreener-App
7.9802
0.25%
0.0098
Schlusskurs vom Vortag:
$7.99
Offen:
$8.13
24-Stunden-Volumen:
1.10M
Relative Volume:
0.60
Marktkapitalisierung:
$584.33M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-38.18M
KGV:
-11.38
EPS:
-0.701
Netto-Cashflow:
$-38.90M
1W Leistung:
+4.57%
1M Leistung:
+23.23%
6M Leistung:
+73.38%
1J Leistung:
+47.51%
1-Tages-Spanne:
$7.955
$8.2998
1-Wochen-Bereich:
$7.53
$8.34
52-Wochen-Spanne:
$4.35
$9.27
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
7.975 | 585.43M | 31,000 | -38.18M | -38.90M | -0.701 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.57 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.28 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - simplywall.st
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade - MSN
Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data - Yahoo Finance
Candel Therapeutics reported better-than-feared Q1 loss – but all eyes turn to this pivotal event tomorrow - MSN
Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs - Traders Union
Behavioral Patterns of CADL and Institutional Flows - Stock Traders Daily
Candel Therapeutics reports positive phase 3 prostate cancer trial data - MSN
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Raises Target Price to $9 - Moomoo
BofA raises Candel Therapeutics stock price target on prostate cancer data - Investing.com UK
BofA raises Candel Therapeutics stock price target on prostate cancer data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data - Dailyhunt
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting - The Manila Times
Candel reports extended phase 3 prostate cancer trial results - Investing.com UK
Candel Therapeutics Inc presents new extended follow-up phase 3 data for CAN-2409 in prostate cancer - Traders Union
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data - TipRanks
Candel Therapeutics reports extended clinical benefit over multiple clinical endpoints in patients from phase 3 trial of aglatimagene besadenovec (CAN-2409) - marketscreener.com
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409) - TradingView
Phase 3 prostate cancer data highlight Candel Therapeutics (NASDAQ: CADL) - Stock Titan
Candel Therapeutics : CADL AUA Investor Call final deck 3PM 5.14.26 IR - marketscreener.com
CCORF Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $25 - Moomoo
RTW Funds and Roderick Wong Hold 8.8% of Candel Therapeutics (NASDAQ: CADL) - Stock Titan
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Prostate cancer drug from Candel extends disease-free survival in phase 3 trial - Stock Titan
Candel Therapeutics : Website Candel May 2026 Corporate Presentation 230AM 05.14.26 IR - marketscreener.com
Candel Therapeutics, Inc. 10-Q Quarterly Report March 31, 2026: Financial Highlights, Risk Factors, and Company Overview - Minichart
Candel Therapeutics, Inc. celebrates Susan Stewart recognition in RAPSorg milestone honors - Traders Union
Candel Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Candel Therapeutics Reports Q1 2026 Results, Advances Towards BLA Submission for Aglatimagene in Prostate Cancer and Prepares Commercial Launch with EVERSANA - Minichart
Candel Therapeutics: Cash, Cash Equivalents of $194.8M, as of March 31, 2026, Expected Sufficient to Fund Co's Current Operating Plan Into Q1 2028 >CADL - Moomoo
Candel Therapeutics 1Q 2026: Net income $(8.9)M, EPS $(0.14) — 10-Q Summary - TradingView
Candel Therapeutics (NASDAQ: CADL) widens R&D loss but ends Q1 2026 with $194.8M cash - Stock Titan
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Globe and Mail
Candel Therapeutics reports Q1 2026 results; net loss $8.9M, cash $194.8M - TradingView
Candel Therapeutics 4Q Loss/Shr 14c >CADL - Moomoo
Candel Therapeutics reports Q1 loss - TradingView
Candel Therapeutics (NASDAQ: CADL) posts Q1 loss, ends quarter with $194.8M cash - Stock Titan
the real run is about to begin - Moomoo
Candel Therapeutics to Present at Upcoming Investor Conferences - marketscreener.com
TradingKey - TradingKey
U.S. Earnings Preview: Before Market Open May 12 - Moomoo
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages - MarketBeat
Candel Therapeutics CEO urges stronger patient role to drive innovation at BioEquityEurope - Traders Union
Candel to discuss phase 3 prostate cancer trial data on May 15 - Investing.com UK
Candel to discuss phase 3 prostate cancer trial data on May 15 By Investing.com - Investing.com South Africa
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Candel Therapeutics Inc-Aktie (CADL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Option Exercise |
1.29 |
937 |
1,209 |
53,430 |
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):